2959 |
Endovascular Therapies for Resistant Hypertension - The ROX 1 Year Results |
Krishna Rocha-Singh |
Apr. 21. 16 |
2958 |
EVAR - Evolving Techniques and Devices |
Robert Bersin |
Apr. 21. 16 |
2957 |
Pitfalls with Comparative Assessment of BRS and DES with Angio, IVUS and OCT |
Patrick W. Serruys |
Apr. 21. 16 |
2956 |
Carotid Stenting for Asymptomatic Carotid Stenosis - Will ACT 1 Change Anything? |
Richard R. Heuser |
Apr. 21. 16 |
2955 |
Bioabsorbable Metallic Scaffolds |
Michael Haude |
Apr. 21. 16 |
2954 |
Drug Coated Balloons for Femoropopliteal Disease - Insights from Randomized Trials and Global Registries |
John Robert Laird, Jr. |
Apr. 21. 16 |
2953 |
PCSK9 Inhibitors & Beyond the Limits: Why Reducing LDL-C Matters? |
Ki Hoon Han |
Apr. 21. 16 |
2952 |
BRS in Bifurcated Lesion and CTO |
Sunao Nakamura |
Apr. 21. 16 |
2951 |
Contemporary Practice and Technical Aspects in PCI with BRS: A European Perspective |
Davide Capodanno |
Apr. 21. 16 |
2950 |
Revisiting Anticoagulants: Why Dual Pathway Inhibition Is Not Back? |
Roxana Mehran |
Apr. 21. 16 |